🧵 Real-World Efficacy & Safety of Ciltacabtagene Autoleucel (Cilta-cel) in Multiple Myeloma 1️⃣ Study Snapshot Real-world (RW) data compared cilta-cel outcomes in relapsed/refractory MM vs the pivotal CARTITUDE-1 trial 💥 Despite higher-risk features, survival outcomes were

sciencedirect.com/science/articl… #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC USMIRC News OncoAlert #سرطان_الدم #المايلوما

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial #MedEd #MedTwitter #mmsm #myeloma #USMIRC USMIRC News sciencedirect.com/science/articl…

Experts discuss how prophylactic steroid or tocilizumab use may prevent CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma. hubs.li/Q03N0fYl0 #mmsm #ICE_TCongress | Prerna Mewawalla Shebli Atrash KU Cancer Center

CancerNetwork® Shebli Atrash KU Cancer Center USMIRC News

Our speakers during regional ICE-T congress discussing how prophylactic steroid or tocilizumab use may prevent CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma! #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC USMIRC News OncoAlert

Our speakers from the regional ICE-T congress discussing: CD20 Bispecifics vs CAR T: Evaluating CRS and ICANS in Lymphoma Nausheen Ahmed MD KU Cancer Center 💻 cancernetwork.com/view/cd20-bisp… #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC USMIRC News OncoAlert #سرطان_الدم #المايلوما

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial #ICE_T #MedEd #medtwitter #mmsm #myeloma #USMIRC USMIRC News sciencedirect.com/science/articl…

🕊️ It is with great sadness that we hear of the passing of Dr. Brian G.M. Durie, co-founder of the International Myeloma Foundation (IMF). A true pioneer, mentor, and visionary whose work transformed the lives of countless patients and physicians around the world. His legacy will

A brief updates for October 2025: #myeloma #MedTwitter #MedEd #mmsm #hematology #CancerAwareness #FDA U.S. FDA USMIRC News #USMIRC Shebli Atrash Muhammad Umair Mushtaq (Abu Mikael) Al-Ola A Abdallah MD (USMIRC)

Honored to welcome Dr. Khalid Halaleh, Director of Adult BMT & Cellular Therapy at KHCC, Jordan, to the KUMC Global Visitor Transplantation and Cellular Therapy Program! A step forward in global collaboration, skill exchange, and innovation in hematopoietic cell transplantation

Enjoying wonderful hospitality from our Saudi colleague Ghazi Alotaibi here in Riyadh — perfect weather and even better company 🇸🇦☀️ #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC USMIRC News OncoAlert #سرطان_الدم #المايلوما

Thank you Dr. Al-Ola Abdallah for the great talk on CAR T at SOHO Saudi Arabia. ⁦Al-Ola A Abdallah MD (USMIRC)⁩ ⁦مستشفى الملك فيصل التخصصي ومركز الأبحاث⁩ ⁦Society of Hematologic Oncology (SOHO)⁩ ⁦University of Kansas⁩

Had such a beautiful tour at #BujairiTerrace after day one of #SOHOKSA! Huge thanks to our amazing Saudi hematologist and ASCT colleagues for the warm hospitality and great company. 🌟🇸🇦 #ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC USMIRC News OncoAlert #سرطان_الدم

Honored to give two talks in the Myeloma session at #SOHOKSA! Huge thanks to our KSA Hematology/BMT colleagues for the warm welcome and collaboration. Kudos to the organizing comiittee for an outstandingly organized conference! First time in Riyadh—won’t be the last! 🌟🙌🇸🇦

CAR-T Outcomes in Post-Allo-Relapsed ALL review Moazzam Shahzad, MD Mikael Rayaan Foundation USMIRC News sciencedirect.com/science/articl…

AML-911: Incidence, Patterns, and Outcomes of Invasive Fungal Infections... Moazzam Shahzad, MD Mikael Rayaan Foundation USMIRC News sciencedirect.com/science/articl…

ABCL-905: Outcomes in Patients With Late Relapse of DLBCL... Moazzam Shahzad, MD Mikael Rayaan Foundation USMIRC News sciencedirect.com/science/articl…

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in R/R-MM ... USMIRC News sciencedirect.com/science/articl…

Shahzad M … Mushtaq MU. Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis. Leukemia & Lymphoma. 2025 Mikael Rayaan Foundation USMIRC News Moazzam Shahzad, MD doi.org/10.1080/104281…